Analysis of immune infiltrate revealed that tumor-infiltrating lymphocytes (TIL) derived from UroA-treated T cells expressed lower level of PD-1 and TIM3 (Fig. 2G). This evidence concerns the gene HAVCR2 and neoplasm.